☰

Laurie K. McNamara, Ph.D. - Publications

Affiliations: 
2009 Integrated Graduate Program in the Life Sciences Northwestern University, Evanston, IL 
Area:
Biochemistry, General Biophysics
Tree Info Similar researchers PubMed Report error

7 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2011 McNamara LK, Brunzelle JS, Schavocky JP, Watterson DM, Grum-Tokars V. Site-directed mutagenesis of the glycine-rich loop of death associated protein kinase (DAPK) identifies it as a key structure for catalytic activity. Biochimica Et Biophysica Acta. 1813: 1068-73. PMID 21126544 DOI: 10.1016/J.Bbamcr.2010.11.011  0.538
2010 Zimmermann M, Atmanene C, Xu Q, Fouillen L, Van Dorsselaer A, Bonnet D, Marsol C, Hibert M, Sanglier-Cianferani S, Pigault C, McNamara LK, Watterson DM, Haiech J, Kilhoffer MC. Homodimerization of the death-associated protein kinase catalytic domain: development of a new small molecule fluorescent reporter. Plos One. 5: e14120. PMID 21152427 DOI: 10.1371/Journal.Pone.0014120  0.593
2009 McNamara LK, Watterson DM, Brunzelle JS. Structural insight into nucleotide recognition by human death-associated protein kinase. Acta Crystallographica. Section D, Biological Crystallography. 65: 241-8. PMID 19237746 DOI: 10.1107/S0907444908043679  0.592
2008 McNamara LK, Schavocky JP, Brunzelle JS, Watterson DM. P3-304: Death associated protein kinase (DAPK): A calcium/calmodulin (CAM) regulator of neuronal apoptosis that is a drug discovery target for neurodegenerative disorders Alzheimer's & Dementia. 4: T611-T611. DOI: 10.1016/J.Jalz.2008.05.1873  0.579
2008 Borders AS, McNamara LK, Roy SM, Chico LW, Pishchulina A, de Almeida LM, Van Eldik LJ, Watterson DM. P2-419: Development of novel protein kinase inhibitors as experimental therapeutics for neurodegenerative disorders Alzheimer's & Dementia. 4: T496-T496. DOI: 10.1016/J.Jalz.2008.05.1498  0.583
2007 Munoz L, Ralay Ranaivo H, Roy SM, Hu W, Craft JM, McNamara LK, Chico LW, Van Eldik LJ, Watterson DM. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. Journal of Neuroinflammation. 4: 21. PMID 17784957 DOI: 10.1186/1742-2094-4-21  0.509
2007 Watterson D, Ranaivo HR, Behanna H, Roy SM, Wing LK, Hu W, Munoz L, Guo L, McNamara LK, Van Eldik LJ. P-014: Improving the CNS drug discovery process: Case study with an integrative approach yielding novel potential disease-modifying therapies Alzheimer's & Dementia. 3: S99-S99. DOI: 10.1016/J.Jalz.2007.04.230  0.46
Show low-probability matches.